Compare BNL & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNL | ERAS |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.0B |
| IPO Year | 2008 | 2021 |
| Metric | BNL | ERAS |
|---|---|---|
| Price | $22.39 | $18.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $20.22 | $14.25 |
| AVG Volume (30 Days) | 1.9M | ★ 5.0M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.87% | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $454,138,000.00 | N/A |
| Revenue This Year | $7.93 | N/A |
| Revenue Next Year | $5.45 | N/A |
| P/E Ratio | $93.17 | ★ N/A |
| Revenue Growth | ★ 5.17 | N/A |
| 52 Week Low | $15.77 | $1.33 |
| 52 Week High | $23.10 | $24.28 |
| Indicator | BNL | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 65.14 | 58.97 |
| Support Level | $19.60 | $17.63 |
| Resistance Level | $23.10 | $21.60 |
| Average True Range (ATR) | 0.44 | 1.29 |
| MACD | 0.01 | -0.18 |
| Stochastic Oscillator | 75.68 | 41.03 |
Broadstone Net Lease Inc is an internally managed real estate investment trust that invests in, owns, and manages single-tenant commercial real estate properties that are net leased on a long-term basis to a diversified group of tenants. The company has selectively invested in net leased assets in the industrial, healthcare, restaurant, retail, and office property types. The company focuses on investing in real estate that is operated by creditworthy single tenants in industries characterized by positive business drivers and trends. The company targets properties that are an integral part of the tenants' businesses and are therefore opportunities to secure long-term net leases.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.